2538-P: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR)
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2538-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SEON MYEONG LEE und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: A novel UCN2 analog, HM17321, was developed to enhance CRFR2 selectivity and extend therapeutic benefits beyond improvements in weight loss quality (WLQ) to include the cardiovascular and renal systems. Here, we investigated the effects of HM17321 on renal dysfunction and explored the underlying mechanisms.
Methods
Renal and cardiovascular effects of HM17321 were evaluated in SHR. Blood pressure (BP) was continuously monitored by telemetry, and a long-term efficacy study assessed renal and cardiac outcomes, with semaglutide (Sema) as a comparator.
Results
In SHR, HM17321 reduced systemic BP and heart rate, with concomitant increases in blood NO levels, suggesting NO-mediated vasodilation and a strong potential to improve cardiovascular (CV) risk. In a 4-month study, HM17321 consistently improved WLQ, as evidenced by marked fat mass reduction (up to -45.5 percentage points vs. SHR) and lean mass gain (up to +9.7 percentage points) with no change in body weight. Notably, HM17321 prevented progressive renal function deterioration observed in vehicle- and Sema-treated SHR. Urinary albumin-to-creatinine ratio and 24-hour urinary albumin excretion were significantly reduced by HM17321 at 300 nmol/kg to 45.5% and 42.2% of vehicle-treated SHR levels, respectively. HM17321 also significantly attenuated cardiac hypertrophy, as evidenced by reduced heart weight. Comprehensive tissue-level analyses of cardiac and renal remodeling are currently underway. Additional mechanistic studies will further delineate the potential direct renal protective effects of HM17321 beyond BP-lowering-mediated benefits.
Conclusion
HM17321 exerted integrated cardiovascular and renal protective effects in preclinical models of hypertension and kidney injury. Beyond its favorable impact on WLQ as a next-generation obesity therapy, HM17321 attenuated the progression of renal dysfunction, supporting its potential applicability as a therapeutic strategy for cardiorenal diseases. Disclosure S. Lee: None. E. Kim: None. Y. Kim: None. D. Lee: None. E. Park: Employee; Current; Hanmi Pharm. Co., Ltd. B. Ye: Employee; Current; Hanmi Pharm. Co., Ltd. J. Kim: Employee; Current; Hanmi Pharm. Co., Ltd. J. Kim: None. S. Bae: None. S. Lee: Employee; Current; Hanmi Pharm. Co., Ltd. I. Choi: None.
Zitieren
APA
LEE, S. M., KIM, E., KIM, Y., LEE, D., PARK, E., YE, B., KIM, J. A., KIM, J. K., BAE, S., LEE, S. H., & CHOI, I. Y. (2026). 2538-P: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR). Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2538-p
Vancouver
LEE SM, KIM E, KIM Y, LEE D, PARK E, YE B, et al. 2538-P: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR). Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2538-p
BibTeX
@article{LEE2026,
author = {LEE, SEON MYEONG and KIM, EUNSEON and KIM, YOHAN and LEE, DAHAE and PARK, EUNJIN and YE, BYEONGJIN and KIM, JEONG A and KIM, JUNG KUK and BAE, SUNGMIN and LEE, SANG HYUN and CHOI, IN YOUNG},
title = {2538-P: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR)},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2538-p}
}
EUVIMED